Technetium Tc-99m arcitumomab
Identification
- Name
- Technetium Tc-99m arcitumomab
- Accession Number
- DB00113
- Description
Reduced Fab fragment of the murine IgG1 monoclonal antibody IMMU-4 (also called NP-4) with specificity for carcinoembryonic antigen (CEA) covalently labeled with Technitium 99. The molecule has a molecular weight of ~54,000 Daltons.
- Type
- Biotech
- Groups
- Experimental
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Protein Structure
- Protein Chemical Formula
- C6398H9900N1714O1995S54
- Protein Average Weight
- 144482.5 Da
- Sequences
>1clo:Anti-CEA heavy chain 1 EVKLVESGGGLVQPGGSLRLSCATSGFTFTDYYMNWVRQPPGKALEWLGFIGNKANGYTT EYSASVKGRFTISRDKSQSILYLQMNTLRAEDSATYYCTRDRGLRFYFDYWGQGTTLTVS SAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQS DLYTLSSSVTVPSSPRPSETVTCNVAHPASSTKVDKKIVPRDCPPCKCPAPNLLGGPSVF IFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLR VVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKK QVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERN SYSCSVVHEGLHNHHTTKSFSR
>1clo: Anti-CEA antigen light chain 1 QTVLSQSPAILSASPGEKVTMTCRASSSVTYIHWYQQKPGSSPKSWIYATSNLASGVPAR FSGSGSGTSYSLTISRVEAEDAATYYCQHWSSKPPTFGGGTKLEIKRADAAPTVSIFPPS SEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTL TKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC
>1clo:Anti-CEA heavy chain 2 EVKLVESGGGLVQPGGSLRLSCATSGFTFTDYYMNWVRQPPGKALEWLGFIGNKANGYTT EYSASVKGRFTISRDKSQSILYLQMNTLRAEDSATYYCTRDRGLRFYFDYWGQGTTLTVS SAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQS DLYTLSSSVTVPSSPRPSETVTCNVAHPASSTKVDKKIVPRDCPPCKCPAPNLLGGPSVF IFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLR VVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKK QVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERN SYSCSVVHEGLHNHHTTKSFSR
>1clo: Anti-CEA antigen light chain 2 QTVLSQSPAILSASPGEKVTMTCRASSSVTYIHWYQQKPGSSPKSWIYATSNLASGVPAR FSGSGSGTSYSLTISRVEAEDAATYYCQHWSSKPPTFGGGTKLEIKRADAAPTVSIFPPS SEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTL TKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC
Download FASTA Format- Synonyms
- Arcitumomab technetium-99m
- Technetium (99mTc) arcitumomab
- Technetium Tc 99m arcitumomab
- Technetium-99m arcitumomab
Pharmacology
- Indication
For imaging colorectal tumors
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
Binds to the carcinoembryonic antigen, which is a cell surface protein generally overexpressed in colon (and other) cancers. The radioactive Tc99, which is covalently attached to the antibody, allows radiodiagnostic detection of CEA expressing cells and tumors
- Mechanism of action
Binds selectively to cell-surface carcinoembryonic antigen (CEA) expressed on colorectal tumors.
Target Actions Organism UCarcinoembryonic antigen-related cell adhesion molecule 1 other/unknownHumans - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
Most likely removed by opsonization via the reticuloendothelial system, or by human antimurine antibody production
- Route of elimination
- Not Available
- Half-life
Approximately 1 hour
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Technetium Tc-99m arcitumomab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Technetium Tc-99m arcitumomab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Technetium Tc-99m arcitumomab. Alirocumab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Alirocumab. Ansuvimab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ansuvimab. Anthrax immune globulin human The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Anthrax immune globulin human. Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Antilymphocyte immunoglobulin (horse). Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Technetium Tc-99m arcitumomab. Asfotase alfa The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Asfotase alfa. Atezolizumab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Atezolizumab. Additional Data Available- Extended DescriptionExtended DescriptionAvailable for Purchase
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - SeveritySeverityAvailable for Purchase
A severity rating for each drug interaction, from minor to major.
Learn more - Evidence LevelEvidence LevelAvailable for Purchase
A rating for the strength of the evidence supporting each drug interaction.
Learn more - ActionActionAvailable for Purchase
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
Products
- International/Other Brands
- CEA-Scan (Immunomedics Inc)
Categories
- ATC Codes
- V09IA06 — Technetium (99mtc) arcitumomab
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- 029JF1SCU8
- CAS number
- 154361-49-6
References
- General References
- External Links
- PubChem Substance
- 46507781
- 230435
- ChEMBL
- CHEMBL2108253
- Therapeutic Targets Database
- DAP001303
- PharmGKB
- PA164746540
- Wikipedia
- Arcitumomab
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Immunomedics Inc.
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Liquid
- Experimental Properties
Property Value Source melting point (°C) 61 °C (FAB fragment), 71 °C (whole mAb) Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000) hydrophobicity -0.423 Not Available isoelectric point 8.26 Not Available
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Other/unknown
- General Function
- Protein homodimerization activity
- Specific Function
- Not Available
- Gene Name
- CEACAM1
- Uniprot ID
- P13688
- Uniprot Name
- Carcinoembryonic antigen-related cell adhesion molecule 1
- Molecular Weight
- 57559.965 Da
References
- Fuster D, Maurel J, Muxi A, Setoain X, Ayuso C, Martin F, Ortega ML, Fuertes S, Pons F: Is there a role for (99m)Tc-anti-CEA monoclonal antibody imaging in the diagnosis of recurrent colorectal carcinoma? Q J Nucl Med. 2003 Jun;47(2):109-15. [PubMed:12865871]
- Hughes K, Pinsky CM, Petrelli NJ, Moffat FL, Patt YZ, Hammershaimb L, Goldenberg DM: Use of carcinoembryonic antigen radioimmunodetection and computed tomography for predicting the resectability of recurrent colorectal cancer. Ann Surg. 1997 Nov;226(5):621-31. [PubMed:9389396]
Drug created on June 13, 2005 07:24 / Updated on January 03, 2021 09:35